Source:http://linkedlifedata.com/resource/pubmed/id/15457680
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-10-1
|
| pubmed:abstractText |
To detect and characterize polymerase gene (pol) polymorphisms and mutation patterns in HIV-1C-infected Batswana patients treated with reverse transcriptase inhibitors, samples from AIDS patients treated with highly active antiretroviral therapy (HAART) were sequenced for the region encompassing the entire HIV-1 protease (PR) and the first 335 amino acids of reverse transcriptase (RT). Amongst the 16 patients treated with antiretroviral (ARV) drugs, eight started HAART regimens containing didanosine, stavudine and nevirapine (ddI/d4T/NVP) or efavirenz (EFV) (arm A) while the others started with zidovudine (AZT) and lamivudine (3TC) given together as combivir (CBV) with either NVP or EFV as arm B. Arm B is the first line regimen currently provided by the Botswana ARV national programme. Greater efficacy, in terms of treatment duration, was observed in patients in arm B (14 months) as compared with patients in arm A (9 months); P<0.05, n=8. Appearance of the M184V mutation in the arm B patients coincided with a rebound of viral load (VL) (4.3 +/-0.1 log10 RNA copies/ml) and a significantly improved immunological parameter (deltaCD4=207.0+/-48.1 cells/microl; P<0.05). Interestingly, patients developing the M184V mutation preferentially harboured polymorphisms Q174K and/or I178L located in close proximity to pol position 184. The M184V mutation occurred following a clear clinical benefit consisting of increased CD4 cell counts and lower plasma viral loads. Primary mutations known to be associated with NNRTI and NRTI resistance for HIV-1B were observed in 10 of the 16 treated patients.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0956-3202
|
| pubmed:author |
pubmed-author:AvalosAvaA,
pubmed-author:BussmannHermannH,
pubmed-author:CardielloPeterP,
pubmed-author:Doualla-BellFlorenceF,
pubmed-author:EssexMaxM,
pubmed-author:GaseitsiweSimaneS,
pubmed-author:MarlinkRichardR,
pubmed-author:ModukaneleMusetsanagepeM,
pubmed-author:MoffatHowardH,
pubmed-author:NdungúThumbiT,
pubmed-author:NovitskyVladimirV,
pubmed-author:PeterTrevorT,
pubmed-author:TendaniGaolatheG,
pubmed-author:ThiorIbouI,
pubmed-author:WainbergMark AMA,
pubmed-author:WesterWilliamW,
pubmed-author:XXX
|
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
189-200
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:15457680-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:15457680-Anti-HIV Agents,
pubmed-meshheading:15457680-Botswana,
pubmed-meshheading:15457680-Epitopes, T-Lymphocyte,
pubmed-meshheading:15457680-Follow-Up Studies,
pubmed-meshheading:15457680-HIV Protease,
pubmed-meshheading:15457680-HIV-1,
pubmed-meshheading:15457680-Humans,
pubmed-meshheading:15457680-Mutation,
pubmed-meshheading:15457680-Phylogeny,
pubmed-meshheading:15457680-Polymorphism, Genetic,
pubmed-meshheading:15457680-RNA-Directed DNA Polymerase,
pubmed-meshheading:15457680-T-Lymphocytes
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.
|
| pubmed:affiliation |
Botswana-Harvard AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|